Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 9/20 | 0.45 |
| ▸ | JAK1 | P23458 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14708344 | 1.00 | JAK3 (0.45) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL17350087 | 1.00 | JAK3 (0.45) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL17350088 | 1.00 | JAK3 (0.45) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL14697424 | 1.00 | JAK3 (0.45) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL14697519 | 0.93 | JAK3 (0.54) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL17350174 | 0.93 | JAK3 (0.54) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL16477599 | 0.93 | JAK3 (0.54) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL17350173 | 0.93 | JAK3 (0.54) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL17350212 | 0.93 | JAK3 (0.54) | JAK3JAK1JAK2TYK2HSD11B1 | |
| SCHEMBL566820 | 0.91 | JAK1 (0.42) | JAK3JAK1JAK2TYK2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556187-B2 | Substituted pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-3112370-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-04-14 | — | — | US | disclosed |
| US-9216999-B2 | Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102102-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AND JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK3 3/4885JAK1 2/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.